Results 141 to 150 of about 106,022 (294)

GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity

The Journal of Clinical Investigation
Glucagon-like peptide-1 (GLP-1) was initially considered to be a hormone with a predominant role in regulating glucose metabolism by inducing insulin secretion, reducing glucagon secretion, and ameliorating insulin resistance, with the last effect being ...
Mark E. Cooper, Daniël H. van Raalte
doaj   +1 more source

Glucagon-like peptide-1 receptor agonists and rotator cuff disease: a scoping review. [PDF]

BMC Musculoskelet Disord
Duru DO, Zhou AK, Lee DKR, Carroll PJ, Elmaraghy A.   +4 more
europepmc   +1 more source

Monogenic and syndromic obesity in children: Clinical recognition, genetics, and precision management

Pediatric Investigation, EarlyView.
Monogenic and syndromic obesity in children often arises from defects in the leptin–melanocortin pathway. Understanding these rare genetic causes not only clarifies mechanisms of appetite regulation but also enables precision therapies, offering hope beyond lifestyle interventions.
Hadel Khalil, Eugene Feigin, Hussein Zaitoon   +2 more
wiley   +1 more source

When Fat Goes Astray: Your Liver and Pancreas Get Into Trouble

Portal Hypertension &Cirrhosis, EarlyView.
Metabolic dysfunction‐associated steatotic liver disease (MASLD) and intrapancreatic fat deposition (IPFD) are both common manifestations of ectopic fat accumulation. Although they share multiple risk factors, they also show notable differences in pathological features, standardization of diagnosis, and research maturity.
Yuying Chen, Li Ding, Shan Zhao, Weihong Wang, Jing Zhong, Qiang Yan   +5 more
wiley   +1 more source

From cytokine storm to renal scarring in diabetic kidney disease: Biomarkers, risk stratification, and precision therapeutics

Precision Medical Sciences, EarlyView.
Hyperglycemia‐driven cytokine activation initiates a sustained inflammatory cascade in diabetic kidney disease, promoting cellular injury and fibrogenic signaling. Integrating cytokine‐based biomarkers with risk stratification enables precision therapeutics that target inflammation and fibrosis, ultimately aiming to halt progression from early renal ...
Emmanuel Ifeanyi Obeagu
wiley   +1 more source

Hair Loss in Patients on Glucagon-Like Peptide 1 Receptor Agonists: Understanding Risks and Managing Outcomes. [PDF]

Dermatol Ther (Heidelb)
Piraccini BM, Vañó-Galván S, Blume-Peytavi U, Ribet V, Mengeaud V.   +4 more
europepmc   +1 more source

Gut microbiota dysbiosis in the inflammatory pathogenesis of diabetic retinopathy

VIEW, EarlyView.
This graphical abstract illustrates how gut dysbiosis drives diabetic retinopathy through the gut‐retina axis, a process unfolding in three interconnected stages. First, in the gut, a decrease in beneficial bacteria and an increase in pro‐inflammatory taxa compromise the intestinal barrier, causing a “leaky gut” that allows LPS to translocate into the ...
Junyan Hu, Jingxiang Zhong
wiley   +1 more source

The effects of glucagon-like peptide-1 receptor agonists on sympathetic neuron activity. [PDF]

Hypertens Res
Koyanagi Y, Iigaya K, Ikeda K, Onimaru H, Izumizaki M.   +4 more
europepmc   +1 more source

Dipeptidyl Peptidase‐4 Inhibitor Use and Risk of Pemphigus Vulgaris and Foliaceus: A Retrospective Cohort Study Using Databases of the Korea National Health Insurance Claims and the National Health Screening Examination

The Journal of Dermatology, EarlyView.
ABSTRACT Although population‐based studies have reported an increased risk of bullous pemphigoid and pemphigus associated with dipeptidyl peptidase‐4 (DPP‐4) inhibitors, there is limited, well‐designed epidemiological evidence for pemphigus vulgaris (PV), which has only been supported by case reports thus far.
Jaein Lee, Jae Hyun Bae, Seokyung Hahn
wiley   +1 more source

Glucagon-Like Peptide-1 Receptor Agonists Inhibit the Initiation of Toxic Amyloid-β42 Aggregation. [PDF]

J Am Chem Soc
Fallot LB, Anderson CA, Pinc JR, Stevenson A, Schleck MC, Hawryschuk E, Li OZ, Palchak JC, Toole JR, Kubiak Ii RW, Dear AJ, Michaels TCT, Limbocker R.   +12 more
europepmc   +1 more source